Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Barclays analyst Charles Pitman lowered the firm’s price target on Lonza (LZAGY) to CHF 670 from CHF 710 and keeps an Overweight rating on the ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...

Lonza is poised for growth amid margin recovery, onshoring opportunities, and strong profit projections. Read more on LZAGY ...

Full Year 2024 Results Key Financial Results Revenue: CHF6.57b (down 2.1% from FY 2023).

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate.

Explore Lonza Group stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for LZAGF. Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug ...